Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Innova CaptabNSE:INNOVACAP -1.81%46 PEG Ratio is 1.16 as of Jul. 25, 2026, which is 3% below its 10-year median of 1.19. GuruFocus rates NSE:INNOVACAP with a GF Score™ of 46/100. The stock has 6 warning signs investors should review. Among 350 Drug Manufacturers companies, Innova Captab ranks better than 61.14% on this metric.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Innova Captab's PEG Ratio or its related term are showing as below:
NSE:INNOVACAP'
s PEG Ratio Range Over the Past 10 Years
Min: 0.84 Med: 1.19 Max: 1.59
Current: 1.16
During the past 8 years, Innova Captab's highest PEG Ratio was 1.59. The lowest was 0.84. And the median was 1.19.
NSE:INNOVACAP's PEG Ratio is ranked better than 61.14% of 350
companies
in the Drug Manufacturers industry
Industry Median: 1.715
vs NSE:INNOVACAP: 1.16
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Innova Captab (NSE:INNOVACAP) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Innova Captab PEG Ratio Related Terms
Innova Captab PEG Ratio Historical Data
* Premium members only.
The historical data trend for Innova Captab's PEG Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Innova Captab's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Innova Captab PEG Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Innova Captab's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Innova Captab's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Innova Captab (NSE:INNOVACAP) has a PEG Ratio of 1.16 as of Jul. 25, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Innova Captab and its competitors. This is near median its historical median of 1.19. Over the past decade, Innova Captab's PEG Ratio has ranged from 0.84 to 1.59. According to the industry distribution chart, Innova Captab ranks #136 out of 350 companies in the Drug Manufacturers industry, placing it in the top 38.9%.
Is Innova Captab's PEG Ratio too high?
Innova Captab's current PEG Ratio of 1.16 is near median its 10-year median of 1.19. Over the past 10 years, this metric has ranged from a low of 0.84 to a high of 1.59. The Drug Manufacturers industry median PEG Ratio is 1.72. Innova Captab's value of 1.16 is 32.4% below this industry median. Based on the distribution chart, Innova Captab ranks #136 out of 350 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Innova Captab has a GF Score™ of 46/100, reflecting its overall financial health beyond just this single metric.
How does Innova Captab's PEG Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Innova Captab ranks #136 out of 350 companies for PEG Ratio. This puts Innova Captab in the upper half of its industry. The industry median PEG Ratio is 1.72. Innova Captab's value of 1.16 is 32.4% below this benchmark. Historically, Innova Captab's own PEG Ratio has ranged from 0.84 to 1.59 over the past decade. While the company's 10-year median is 1.19 vs. the industry median of 1.72, Innova Captab has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Drug Manufacturers company?
The median PEG Ratio among Drug Manufacturers companies is 1.72, based on 350 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Innova Captab's current PEG Ratio of 1.16 is 32.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Innova Captab and its competitors. For the Drug Manufacturers industry, the median PEG Ratio is 1.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Innova Captab's current PEG Ratio is 1.16, which is near median its own 10-year median of 1.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Innova Captab stock overvalued right now?
Innova Captab (NSE:INNOVACAP) has a current PEG Ratio of 1.16. The current PEG Ratio is 1.16, which is near median its 10-year median of 1.19 and 32.4% below the Drug Manufacturers industry median of 1.72. Innova Captab's overall GF Score™ is 46/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For Innova Captab (NSE:INNOVACAP), the current PEG Ratio is 1.16 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Innova Captab Ltd is engaged in the business of manufacturing and trading of drugs and pharmaceuticals. The Company has identified "Drugs and pharmaceutical products" as single operating segment. The company has presence in India, and Outside India. The company generates majority of revenue from India. The company's products are Cephalosporins, Proton Pump Inhibitor, Antocholinergic and Heparin NSAIDs, Analgesics and Antipyretic, Anticold and Antiallergic, Antiemetic, Antidiabetic, Antispasmodic, Antifibrinolytic, Cardiovascular, Antioxidant and Vitamins, Antihyperuricemia and Antigout, Fluoroquinolone and Macrolide, Nootropics and Neurotonics/ Neurotrophics, Antiulcerative, Antimalarial Anxiolytic, Anticonvulsant and Antipsychotic, Bladder and Prostate Disorder, etc.
46GF Score
Get the complete analysis for NSE:INNOVACAP
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:INNOVACAP has been successfully added to your 
